Summary of precautions during use of Nilotinib

Nilotinib is a second-generation tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and some patients with acute lymphoblastic leukemia. As a targeted drug, nilotinib has shown good clinical efficacy, but there are also many matters that need to be paid attention to during its use. Reasonable knowledge of medication precautions is crucial to improving treatment effects and reducing the risk of adverse reactions. The following will provide a detailed summary of drug usage, adverse reaction management, drug interactions, and lifestyle modifications.

Nilotinib must be taken strictly in accordance with the doctor's instructions. It is generally recommended that patients take it on an empty stomach, at least 1 hours before meals or 2 hours after meals to avoid the impact of food on drug absorption. The recommended dose of nilotinib varies depending on the condition and individual patient differences. A common dose is 300 mg or 400 mg twice daily. Patients should not adjust the dosage or stop medication at will, otherwise it may lead to disease progression or drug resistance. At the same time, you should maintain a regular schedule when taking medicine, and try to take it at the same time every day to ensure the stability of blood drug concentration. During the period of taking, blood picture, liver function and electrocardiogram need to be reviewed regularly to detect potential adverse reactions and cardiotoxicity in a timely manner.

Nilotinib may cause a variety of adverse reactions during treatment, and patients need to strengthen self-monitoring. The more common side effects include rash, headache, nausea, diarrhea and muscle cramps, among which rash and gastrointestinal reactions are more common. More serious side effects include cardiac arrhythmias, pancreatitis, liver function abnormalities, and hematologic toxicities (eg, thrombocytopenia). Especially in the heart, nilotinib may cause prolongation of the QT interval and increase the risk of arrhythmia, so electrocardiogram monitoring is required before and during treatment. If you notice symptoms such as palpitations, dizziness or chest pain, you should seek medical advice promptly. In addition, patients with abnormal liver function should use it with caution and adjust the dose according to liver function.

Nilotinib interacts with many drugs, so patients should use it with caution. It is mainly metabolized by hepatic cytochrome P450 3A4 (CYP3A4), so coadministration with CYP3A4 inhibitors or inducers may significantly affect drug concentrations. For example, potentCYP3A4Inhibitors such as ketoconazole and itraconazole may increase the plasma concentration of nilotinib and increase the risk of toxicity; while inducers such as rifampicin and carbamazepine may reduce the efficacy of the drug. In addition, avoid concurrent use of drugs that may prolong the QT interval, such as certain antiarrhythmic drugs, antibiotics, and antipsychotics. Patients should inform their doctors about all medications they take to prevent potential drug interactions.

Patients should also use medications in conjunction with their lifestyle habits to avoid aggravating drug side effects. Alcoholic beverages should be avoided while taking the medicine to reduce the burden on the liver. Nilotinib may cause dyslipidemia. Patients are advised to eat a reasonable diet, control cholesterol and fat intake, and maintain an appropriate weight. Moderate exercise can help improve physical fitness, but avoid excessive fatigue. Because nilotinib may affect blood sugar, patients with diabetes need to closely monitor blood sugar changes. Regular follow-up visits and laboratory examinations are important links to ensure the safety and effectiveness of treatment. Patients should actively cooperate with the doctor's arrangements.

In summary, nilotinib plays an important role in the treatment of chronic myelogenous leukemia and other diseases, but there are many precautions during its use. Patients should strictly follow the doctor's instructions, be alert to and manage adverse reactions, prevent drug interactions, and adjust their lifestyle to ensure the safety and effectiveness of treatment. Through close cooperation between doctors and patients, the therapeutic benefits of nilotinib can be maximized and patients' prognosis and quality of life can be improved.

Reference materials:https://www.drugs.com/